GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » ROA %

Cytophage Technologies (TSXV:CYTO) ROA % : -64.77% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Cytophage Technologies's annualized Net Income for the quarter that ended in Sep. 2024 was C$-4.36 Mil. Cytophage Technologies's average Total Assets over the quarter that ended in Sep. 2024 was C$6.73 Mil. Therefore, Cytophage Technologies's annualized ROA % for the quarter that ended in Sep. 2024 was -64.77%.

The historical rank and industry rank for Cytophage Technologies's ROA % or its related term are showing as below:

TSXV:CYTO' s ROA % Range Over the Past 10 Years
Min: -55.62   Med: -14.83   Max: 0.48
Current: -55.62

During the past 3 years, Cytophage Technologies's highest ROA % was 0.48%. The lowest was -55.62%. And the median was -14.83%.

TSXV:CYTO's ROA % is ranked worse than
65.2% of 1503 companies
in the Biotechnology industry
Industry Median: -35.81 vs TSXV:CYTO: -55.62

Cytophage Technologies ROA % Historical Data

The historical data trend for Cytophage Technologies's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies ROA % Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23
ROA %
-55.47 -14.83 0.48

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only -241.94 380.49 -241.25 -62.12 -64.77

Competitive Comparison of Cytophage Technologies's ROA %

For the Biotechnology subindustry, Cytophage Technologies's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytophage Technologies's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's ROA % distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's ROA % falls into.



Cytophage Technologies ROA % Calculation

Cytophage Technologies's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.022/( (3.69+5.461)/ 2 )
=0.022/4.5755
=0.48 %

Cytophage Technologies's annualized ROA % for the quarter that ended in Sep. 2024 is calculated as:

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-4.356/( (7.313+6.138)/ 2 )
=-4.356/6.7255
=-64.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data. ROA % is displayed in the 30-year financial page.


Cytophage Technologies  (TSXV:CYTO) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-4.356/6.7255
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.356 / 0)*(0 / 6.7255)
=Net Margin %*Asset Turnover
=N/A %*0
=-64.77 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Cytophage Technologies ROA % Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytophage Technologies Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
26 Henlow Bay, Winnipeg, MB, CAN, R3Y 1G4
Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.